By R. Colon-Thillet
Treatment for ovarian cancer across subtypes typically consists of platinum-based chemotherapies. However, this standard therapy is less effective against ovarian clear cell carcinoma (OCCC), a rare subtype of ovarian cancer with distinct pathology and genetic drivers. Advanced … Read more
By Lisa Rapaport
Patients with cancer shouldn’t delay COVID-19 vaccination despite the potential for clinically evident adenopathy on imaging done after vaccination, according to recommendations from a multidisciplinary panel of scientific experts.
Vaccination-associated adenopathy or axillary swelling may appear within … Read more
The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.
By Courtney Marabella
The FDA has granted priority review to the new
By Christina Bennett, MS
The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more
For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more
An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
By Courtney Marabella… Read more
By Matthew Stenger
In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease … Read more
Eleven years ago, my wife and I had the rug pulled out from under us. Michelle was diagnosed with ovarian cancer, and we were thrust into a new, alien world—Michelle as patient, and me as caregiver—a role I frankly wasn’t … Read more
When diagnosed, there’s so much to deal with. After years of warning signs and my primary care doctor treating me for a myriad of medical issues, I presented with excruciating torso and belly pain, a distended stomach & difficulty breathing … Read more
All cells use sugar as a vital source of energy and building blocks. Unfortunately, that means even cancer cells use sugar. Researchers at Memorial Sloan Kettering (MSK) Cancer Center wondered what happens when tumor cells and immune cells battle for … Read more
By Sandee LaMotte, CNN
A genetic test used to detect common traits many people share is not reliable in identifying rare disease-causing variations, such as those that can predict breast and ovarian cancer, a new study has found.
The SNP … Read more
The study finally paves the way for the use of antibodies different from IgG as immunotherapeutic agents for at least tumors currently resistant to conventional immune checkpoint blockade.
The prognosis of ovarian cancer is poor, with an estimated five-year survival … Read more
By Ian Ingram
Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed.
For the primary endpoint of progression-free survival … Read more
By Mark L. Fuerst
Women who receive ovarian stimulation for assisted reproductive technology (ART) procedures don’t have an increased risk of developing ovarian cancer when compared to subfertile women who don’t undergo ART, according to a new study.
The results … Read more
On December 17, 2020, the American Society of Clinical Oncology and Infectious Diseases Society of America held a “COVID-19 Vaccine & Patients with Cancer” webinar to discuss the importance of COVID-19 vaccination and to provide expert opinion on its use … Read more
Loss of ARID1A causes increased glutamine metabolism, which can be blocked pharmacologically to target ARID1A-mutant tumors.
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according … Read more